NKG2A is a marker for acquisition of reg
β
Vitaly Ablamunits; Octavian Henegariu; Paula Preston-Hurlburt; Kevan C. Herold
π
Article
π
2011
π
John Wiley and Sons
π
English
β 435 KB
π 1 views
## Abstract Treatment with antiβCD3 mAb modulates immune responses that cause type 1 diabetes and other diseases. CD8^+^ Tregs can be induced in vitro and in vivo by mAb. However, 1/3 of patients do not respond to drug therapy and in an equal proportion, antiβCD3 mAb does not induce Tregs in vitro.